BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will present new clinical research across its antibody drug conjugate (ADC) portfolio with more than 25 abstracts across multiple types of cancer at the IASLC 2024 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC24) and the 2024 European Society for Medical Oncology (#ESMO24)..

新泽西州BASKING RIDGE（商业新闻短讯）--Daiichi Sankyo（东京证交所：4568）将在由国际肺癌研究协会（WCLC24）和2024年欧洲医学肿瘤学会（ESMO24）主办的IASLC 2024年世界肺癌会议上，展示其抗体-药物偶联物（ADC）组合的新临床研究，其中包括多种类型癌症的超过25篇摘要。。

Data at WCLC and ESMO showcasing Daiichi Sankyo’s progress towards its goal of creating new standards of care for patients with cancer will include six late-breaking presentations, including two back-to-back presentations during Presidential Symposium 1 featuring datopotamab deruxtecan (Dato-DXd) data at WCLC, and the first presentation of clinical data of DS-9606, a CLDN6 directed modified pyrrolobenzodiazepine (PBD) ADC from Daiichi Sankyo’s second ADC platform, at ESMO..

WCLC和ESMO的数据展示了第一三共在为癌症患者创造新的护理标准方面取得的进展，其中包括六次最新的演示，包括在总统研讨会1期间的两次背靠背演示，其中包括在WCLC的达托巴单抗-德鲁替康（Dato-DXd）数据，以及在ESMO首次展示了DS-9606的临床数据，DS-9606是第一三共第二个ADC平台的CLDN6定向修饰吡咯苯并二氮杂卓（PBD）ADC。。

“New data in lung, breast, gastric, ovarian, endometrial and other cancers from several of our DXd antibody drug conjugates demonstrates how we are making substantial progress toward creating new standards of care for patients with cancer,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “We look forward to presenting initial clinical data from our second antibody drug conjugate platform at ESMO, which underscores how Daiichi Sankyo is applying our expertise in this technology to craft new innovation for patients.”.

“我们的几种DXd抗体-药物偶联物在肺癌、乳腺癌、胃癌、卵巢癌、子宫内膜癌和其他癌症方面的新数据表明，我们正在为癌症患者创造新的护理标准方面取得重大进展，”第一三共研发全球负责人Ken Takeshita医学博士说。“我们期待着从ESMO的第二抗体-药物偶联物平台提供初步的临床数据，这强调了第一三共如何应用我们在这项技术方面的专业知识为患者创造新的创新。”。

Progress in Lung Cancer at WCLC and ESMO

WCLC和ESMO肺癌研究进展

Late-breaking data at WCLC to be reported during back-to-back presentations at Presidential Symposium 1 will highlight the first interim results from the NeoCOAST-2 phase 2 platform trial evaluating novel perioperative treatment combinations including one arm studying datopotamab deruxtecan with durvalumab and chemotherapy as neoadjuvant treatment followed by adjuvant treatment with durvalumab in patients with resectable early-stage (IIA to IIIB) non-small cell lung cancer (NSCLC)..

在总统研讨会1的背靠背演讲中报告的WCLC最新数据将突出NeoCOAST-2 2期平台试验的第一个中期结果，该试验评估了新的围手术期治疗组合，包括单臂研究达托单抗-德鲁替康联合durvalumab和化疗作为新辅助治疗，然后在可切除的早期（IIA至IIIB）非小细胞肺癌（NSCLC）患者中使用durvalumab进行辅助治疗。。

The second Presidential Symposium 1 presentation will feature results from the application of quantitative continuous scoring (QCS), AstraZeneca’s proprietary computational pathology platform, to measure TROP2 in tissue samples collected in the TROPION-Lung01 phase 3 trial that evaluated datopotamab deruxtecan versus docetaxel in patients with locally advanced or metastatic NSCLC treated with at least one prior line of therapy.

第二届总统研讨会1的演讲将展示应用定量连续评分（QCS）（阿斯利康专有的计算病理学平台）的结果，以测量在TROPION-Lung01 3期试验中收集的组织样本中的TROP2，该试验评估了达托单抗-德鲁替康与多西紫杉醇在至少一种先前治疗方案治疗的局部晚期或转移性NSCLC患者中的作用。

Overall survival results from TROPION-Lung01 also will be presented as a late-breaking oral presentation..

TROPION-Lung01的总体生存结果也将作为晚期口头报告。。

Other data at WCLC include two oral presentations featuring the interim results from the dose optimization part of the IDeate-Lung01 phase 2 trial of ifinatamab deruxtecan (I-DXd) in patients with pretreated extensive-stage small cell lung cancer and results from the ENHERTU® (trastuzumab deruxtecan) monotherapy arm of the DESTINY-Lung03 phase 1b trial in patients with previously treated HER2 overexpressing unresectable, locally advanced or metastatic NSCLC.

WCLC的其他数据包括两份口头报告，其中包括ifinatamab deruxtecan（I-DXd）治疗广泛期小细胞肺癌患者的IDeate-Lung01 2期试验剂量优化部分的中期结果，以及DESTINY-Lung03 1b期试验的ENHERTU®（曲妥珠单抗deruxtecan）单药治疗组对先前治疗过的HER2过表达不可切除，局部晚期或转移性NSCLC患者的结果。

A trial-in-progress poster from the NSCLC cohort of a phase 1b trial evaluating the combination of datopotamab deruxtecan and valemetostat, a dual inhibitor of EZH1 and EZH2, in previously treated locally advanced, unresectable or metastatic nonsquamous NSCLC with or without actionable genomic alterations also will be highlighted..

来自NSCLC队列的一项1b期临床试验的正在进行中的试验海报评估了达托单抗deruxtecan和valemetostat（EZH1和EZH2的双重抑制剂）在先前治疗的局部晚期，不可切除或转移性非鳞状细胞癌中的组合，无论是否有可行的基因组改变也将被强调。。

At ESMO, additional data in lung cancer being reported include poster presentations featuring a post-hoc analysis of patients with nonsquamous NSCLC by baseline brain metastases status in the TROPION-Lung01 phase 3 trial of datopotamab deruxtecan and intracranial responses seen in the IDeate-Lung01 phase 2 trial of ifinatamab deruxtecan, as well as a trial-in-progress poster featuring the design of the IDeate-Lung03 phase 1b/2 trial of ifinatamab deruxtecan in combination with atezolizumab with or without carboplatin as first-line induction or maintenance therapy in patients with extensive-stage small cell lung cancer..

在ESMO，正在报道的肺癌的其他数据包括海报展示，其中包括达托单抗-德鲁替康的TROPION-Lung01 3期试验中基线脑转移状态对非鳞状细胞癌患者的事后分析，以及在IDeate-Lung01中观察到的颅内反应。艾非那他单抗-德鲁替康的2期试验，以及正在进行的海报，其中设计了艾非那他单抗-德鲁替康联合阿唑珠单抗（含或不含卡铂）作为广泛期小细胞肺癌患者的一线诱导或维持治疗的IDeate-Lung03 1b/2期试验。。

Continued Innovation in Breast Cancer at ESMO

ESMO在乳腺癌方面的持续创新

Late-breaking presentations in breast cancer at ESMO will include a proffered paper session featuring the primary results of the DESTINY-Breast12 phase 3b/4 trial evaluating ENHERTU in patients with HER2 positive advanced or metastatic breast cancer with or without brain metastases, and two mini oral sessions highlighting patient reported outcomes and determination of the HER2 low and HER2 ultralow status of tumors from the DESTINY-Breast06 phase 3 trial in patients with HR positive, HER2 low and HER2 ultralow metastatic breast cancer..

ESMO在乳腺癌方面的最新突破性演讲将包括一次提交的论文会议，该会议将介绍DESTINY-Breast12 3b/4期试验的主要结果，该试验评估了HER2阳性晚期或转移性乳腺癌伴或不伴脑转移患者的ENHERTU，以及两次小型口服会议，重点介绍了患者报告的结果，以及DESTINY-Breast12 3期试验对HR阳性，HER2低和HER2超低转移性乳腺癌患者的HER2低和HER2超低肿瘤状态的确定。。

Two proffered paper sessions will highlight results from the ICARUS-BREAST01 phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR positive, HER2 negative advanced breast cancer with disease progression following two or more treatments and the investigator-initiated ERICA phase 2 trial evaluating olanzapine-based triplet antiemetic therapy for prevention of nausea and vomiting in combination with ENHERTU in patients with metastatic breast cancer.

两次提交的论文会议将重点介绍ICARUS-BRAST01 patritumab deruxtecan（HER3 DXd）2期研究对HR阳性，HER2阴性晚期乳腺癌患者进行两次或多次治疗后疾病进展的结果，以及研究者发起的ERICA 2期试验，评估基于奥氮平的三联止吐疗法，以预防转移性乳腺癌患者的恶心和呕吐。

A mini oral session will feature a supplementary biomarker analysis from the DAISY phase 2 trial evaluating ENHERTU in three cohorts of patients with HER2 expressing metastatic breast cancer and a poster presentation will report on an exploratory biomarker analysis of ENHERTU in patients with HR positive, HER2 low metastatic breast cancer from the DESTINY-Breast04 phase 3 trial.

一个小型口服会议将展示DAISY 2期试验的补充生物标志物分析，评估三组表达HER2的转移性乳腺癌患者的ENHERTU，海报展示将报告HR阳性患者的ENHERTU探索性生物标志物分析，来自DESTINY-Breast04 3期试验的HER2低转移性乳腺癌。

A poster reporting on exposure-adjusted incidence rates of adverse events from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan versus chemotherapy in patients with previously treated HR positive, HER2 negative metastatic breast cancer also will be featured..

还将发布一张海报，报告先前治疗过HR阳性，HER2阴性转移性乳腺癌患者的达托巴单抗deruxtecan与化疗的TROPION-BRAST01 3期试验中暴露调整后的不良事件发生率。。

Data from Daiichi Sankyo’s Second ADC Platform and DXd ADC Data in Multiple Additional Cancers at ESMO

来自Daiichi Sankyo第二个ADC平台的数据和ESMO中多种其他癌症的DXd ADC数据

At ESMO, a proffered paper session will highlight preliminary results from a phase 1 trial of DS-9606, a CLDN6 directed modified PBD ADC from Daiichi Sankyo’s second ADC platform, in patients with solid tumors known to express CLDN6. Results from the DESTINY-Gastric03 phase 1b/2 trial evaluating ENHERTU monotherapy or ENHERTU combinations with chemotherapy and/or immunotherapy in patients with HER2 expressing advanced/metastatic gastric or gastroesophageal junction carcinoma also will be presented at a proffered paper session..

在ESMO，提交的论文会议将重点介绍DS-9606的第一阶段试验的初步结果，DS-9606是来自第一三共第二个ADC平台的CLDN6定向修饰的PBD ADC，用于已知表达CLDN6的实体瘤患者。DESTINY-Gastric03 1b/2期试验的结果评估了表达HER2的晚期/转移性胃癌或胃食管交界癌患者的ENHERTU单药治疗或ENHERTU联合化疗和/或免疫治疗。。

A mini oral session will feature results from the TROPION-PanTumor03 phase 2 trial of datopotamab deruxtecan in patients with previously treated recurrent endometrial or ovarian cancer. Trial-in-progress poster presentations will highlight the HERTHENA-PanTumor01 phase 2 trial evaluating patritumab deruxtecan in patients with a broad range of solid tumors including bladder, cervical, endometrial, esophageal, gastric, head and neck, melanoma, ovarian, pancreatic and prostate and a phase 1 trial of DS-1471, a CD147 monoclonal antibody, in patients with locally advanced or metastatic solid cancers..

一次小型口服会议将展示达托单抗deruxtecan在先前治疗的复发性子宫内膜癌或卵巢癌患者中进行的TROPION-PanTumor03 2期临床试验的结果。正在进行的试验海报展示将重点介绍HERTHENA-PanTumor01 2期试验，该试验评估patritumab deruxtecan治疗多种实体瘤患者，包括膀胱癌，宫颈癌，子宫内膜癌，食道癌，胃癌，头颈癌，黑色素瘤，卵巢癌，胰腺癌和前列腺癌，以及CD147单克隆抗体DS-1471在局部晚期或转移性实体癌患者中的1期试验。。

Investor Conference Call Following ESMO

ESMO之后的投资者电话会议

Daiichi Sankyo will hold a virtual conference call for investors on Tuesday, September 17, 2024 from 8:00 to 9:30 am EDT / 9:00 to 10:30 pm JST. Executives from Daiichi Sankyo will provide an overview of the WCLC and ESMO research data and address questions.

Daiichi Sankyo将于2024年9月17日（星期二）上午8:00至9:30（美国东部夏令时）/晚上9:00至10:30（JST）为投资者举行虚拟电话会议。第一三共的高管将概述WCLC和ESMO的研究数据并解决问题。

WCLC and ESMO Data Highlights

WCLC和ESMO数据亮点

Highlights of data from Daiichi Sankyo’s ADC portfolio at WCLC 2024 include:

2024年WCLC上，第一三共ADC投资组合的数据亮点包括：

Presentation Title

演示文稿标题

Author

作者

Abstract

摘要

Presentation (PDT)

演示文稿（PDT）

NSCLC

非小细胞肺癌

NeoCOAST-2: efficacy and safety of neoadjuvant durvalumab (D) + novel anticancer agents + CT and adjuvant D ± novel agents in resectable NSCLC

NeoCOAST-2：新辅助durvalumab（D）+新型抗癌剂+CT和辅助D±新型药物在可切除NSCLC中的疗效和安全性

T. Cascone

T、 卡斯科内

PL02.07

Presidential Symposium 1

Sunday, September 8

9月8日，星期日

8:30 - 10:00 am

8： 上午30-10:00

Normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung01

通过定量连续评分将TROP2的标准化膜比预测TROPION-Lung01的临床结果

M.C. Garassino

M、 C.加拉西诺

PL02.11

PL02.11

Presidential Symposium 1

总统研讨会1

Sunday, September 8

9月8日，星期日

8:30 - 10:00 am

8： 上午30-10:00

Datopotamab deruxtecan vs docetaxel in patients with non-small cell lung cancer: final overall survival from TROPION-Lung01

达托单抗-德鲁替康与多西紫杉醇治疗非小细胞肺癌：TROPION-Lung01的最终总生存期

J. Sands

J、 沙子

OA08.03

OA08.03

Oral Presentation

口头陈述

Monday, September 9

9月9日，星期一

10:45 - 12:00 pm

10： 下午45-12:00

Trastuzumab deruxtecan monotherapy in pretreated HER2 overexpressing nonsquamous non-small cell lung cancer: DESTINY-Lung03 part 1

曲妥珠单抗-德鲁替康单药治疗预处理过表达HER2的非鳞状非小细胞肺癌：DESTINY-Lung03第1部分

D. Planchard

D、普兰查德

OA16.05

海外账户16.05

Oral Presentation

口头陈述

Tuesday, September 10

9月10日，星期二

1:30 - 2:45 pm

1： 下午30-2:45

Valemetostat and datopotamab deruxtecan in previously treated, advanced, unresectable, or metastatic non-squamous NSCLC

Valemetostat和达托单抗-德鲁替康治疗先前治疗过的，晚期，不可切除或转移性非鳞状NSCLC

A. Spira

A.斯皮拉

P2.10A.04

P2.10A.04

Poster Session

海报会议

Sunday, September 8

9月8日，星期日

6:15 - 7:45 pm

6：

SCLC

SCLC

Ifinatamab deruxtecan (I-DXd) in extensive-stage small cell lung cancer (ES-SCLC): interim analysis of IDeate-Lung01

Ifinatamab deruxtecan（I-DXd）治疗广泛期小细胞肺癌（ES-SCLC）：IDeate-Lung01的中期分析

C. Rudin

C.鲁丁

OA04.03

OA04.03

Oral Presentation

口头陈述

Sunday, September 8

9月8日，星期日

2:00 - 3:15 pm

2： 00-下午3:15

Exposure-response analyses to support phase 3 dose selection for I-DXd (ifinatamab deruxtecan) in extensive stage SCLC patients

暴露-反应分析，以支持广泛期SCLC患者I-DXd（ifinatamab deruxtecan）的3期剂量选择

N. Midde

N.米德

P1.13A.12

P1.13A.12

Poster Session

海报会议

Sunday, September 8

9月8日，星期日

12:00 - 2:00 pm

12： 00-下午2:00

Highlights of data from Daiichi Sankyo’s ADC portfolio at ESMO 2024 include:

在ESMO 2024上，第一三共ADC投资组合的数据亮点包括：

Presentation Title

演示文稿标题

Author

作者

Abstract

摘要

Presentation (CEST)

演示（CEST）

NSCLC

非小细胞肺癌

Datopotamab deruxtecan (Dato-DXd) vs docetaxel in patients with advanced nonsquamous non-small cell lung cancer with brain metastases: results from TROPION-Lung01

Datopotamab deruxtecan（Dato DXd）与多西紫杉醇治疗晚期非鳞状非小细胞肺癌脑转移患者的比较：TROPION-Lung01的结果

E. Pons-Tostivint

E.Pons Tostivint

1312P

1312便士

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

SCLC

SCLC

Intracranial response in patients with baseline brain metastases and extensive-stage small cell lung cancer treated with ifinatamab deruxtecan (I-DXd) in the IDeate-Lung01 study

在IDeate-Lung01研究中，使用ifinatamab deruxtecan（I-DXd）治疗的基线脑转移和广泛期小细胞肺癌患者的颅内反应

M. Johnson

M、 约翰逊

1787P

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

IDeate-Lung03: a phase 1b/2 study of ifinatamab deruxtecan (I-DXd) plus atezolizumab with or without carboplatin as first line induction or maintenance in patients with extensive stage small cell lung cancer

IDeate-Lung03:ifinatamab deruxtecan（I-DXd）联合atezolizumab联合或不联合卡铂作为广泛期小细胞肺癌患者一线诱导或维持的1b/2期研究

C. Rudin

C.鲁丁

1812TiP

1812天

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

BREAST

乳房

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ advanced/metastatic breast cancer with or without brain metastases: primary results from DESTINY-Breast12

曲妥珠单抗-德鲁替康（T-DXd）治疗HER2+晚期/转移性乳腺癌伴或不伴脑转移的患者：DESTINY-Breast12的主要结果

N. Lin

N、 林

LBA18

18磅

Proffered Paper Session

提交的论文会议

Friday, September 13

9月13日，星期五

4:00 - 5:30 pm

4： 00-下午5:30

HER2 low and HER2 ultralow status determination in tumors of patients with HR+ mBC in DESTINY-Breast06

DESTINY-Breast06中HR+mBC患者肿瘤中HER2低和HER2超低状态的测定

G. Viale

维亚尔先生

LBA 21

磅21

Mini Oral Session

小型口头会议

Sunday, September 15

9月15日，星期日

8:30 - 10:00 am

8： 上午30-10:00

Effects of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice on patient-reported outcomes in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2) low/ultralow metastatic breast cancer: results from DESTINY-Breast06

曲妥珠单抗-德鲁替康（T-DXd）与医生选择的治疗对激素受体阳性（HR+），人表皮生长因子受体2（HER2）低/超低转移性乳腺癌患者报告结局的影响：DESTINY-Breast06的结果

X. Hu

十、 胡

LBA22

磅22

Mini Oral Session

小型口头会议

Sunday, September 15

9月15日，星期日

8:30 - 10:00 am

8： 上午30-10:00

Efficacy, safety and biomarker analysis of ICARUS-BREAST01: a phase 2 study of patritumab deruxtecan (HER3-DXd) in patients with HR+/HER2- advanced breast cancer

ICARUS-BREAST01的疗效，安全性和生物标志物分析：patritumab deruxtecan（HER3 DXd）在HR+/HER2晚期乳腺癌患者中的2期研究

B. Pistilli

B.手枪

340O

340度

Proffered Paper Session

提交的论文会议

Friday, September 13

9月13日，星期五

4:00 - 5:30 pm

4： 00-下午5:30

A multicenter, randomized, double-blind, placebo-controlled study of olanzapine-based triplet antiemetic therapy for prevention of delayed and persistent nausea and vomiting induced by trastuzumab deruxtecan in patients with metastatic breast cancer: ERICA study

H. Sakai

H.酒井

1816O

1816度

Proffered Paper Session

提交的论文会议

Saturday, September 14

9月14日，星期六

2:45 - 4:25 pm

2： 下午45-4:25

Unraveling the mechanisms of action and resistance to trastuzumab deruxtecan (T-DXd): supplementary biomarker analyses from DAISY trial

揭示曲妥珠单抗-德鲁替康（T-DXd）的作用机制和耐药性：DAISY试验的补充生物标志物分析

F. Mosele

F.Mosele

343MO

3.43亿

Mini Oral Session

小型口头会议

Sunday, September 15

9月15日，星期日

8:30 - 10:00 am

8： 上午30-10:00

Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor-positive metastatic breast cancer in DESTINY-Breast04

曲妥珠单抗-德鲁替康的探索性生物标志物分析与DESTINY-Breast04中HER2低，激素受体阳性转移性乳腺癌的医生选择治疗

N. Ueno

N、 上野

432P

432便士

Poster Session

海报会议

Monday, September 16

9月16日，星期一

Exposure-adjusted incidence rates of adverse events from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy in patients with pretreated, inoperable/ metastatic HR+/HER2- breast cancer

暴露调整后的不良事件发生率来自TROPION-BRAST01研究的达托单抗deruxtecan（Dato DXd）与研究者对预处理，无法手术/转移性HR+/HER2-乳腺癌患者化疗的选择

H. Rugo

H.鲁戈

431P

431便士

Poster Session

海报会议

Monday, September 16

9月16日，星期一

Treatment patterns and outcomes in HER2 low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States

先前在美国接受内分泌治疗的HER2低，HR+转移性乳腺癌患者的治疗模式和结果

S. Modi

S、 莫迪

399P

399便士

Poster Session

海报会议

Monday, September 16

9月16日，星期一

OTHER SOLID TUMORS

Preliminary results from a phase 1, first-in-human study of DS-9606a, a Claudin 6 (CLDN6) directed antibody drug conjugate, in patients with tumor types known to express CLDN6

在已知表达CLDN6的肿瘤类型的患者中，对DS-9606a（Claudin 6（CLDN6）定向抗体-药物偶联物）进行的第一阶段人体研究的初步结果

M. Patel

M、 帕特尔

610O

6100度

Proffered Paper Session

提交的论文会议

Sunday, September 15

9月15日，星期日

2:45 - 4:15 pm

2： 下午45-4:15

Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients with advanced/metastatic HER2 positive esophageal, gastric or gastroesophageal junction adenocarcinoma: DESTINY-Gastric03

曲妥珠单抗-德鲁替康（T-DXd）单药治疗和联合治疗晚期/转移性HER2阳性食管、胃或胃食管交界腺癌：DESTINY-Gastric03

Y. Janjigian

Y.日语

1401O

1401万

Proffered Paper Session

提交的论文会议

Saturday, September 14

9月14日，星期六

8:30 - 10:00 am

8： 上午30-10:00

Datopotamab deruxtecan (Dato-DXd) monotherapy in patients with endometrial or ovarian cancer: results from the phase 2 TROPION-PanTumor03 study

Datopotamab deruxtecan（Dato DXd）单药治疗子宫内膜癌或卵巢癌：2期TROPION-PanTumor03研究的结果

A.

答：。

Oaknin

正常开放

714MO

7.14亿

Mini Oral Session

小型口头会议

Sunday, September 15

9月15日，星期日

2:45 - 4:15 pm

2： 下午45-4:15

HERTHENA-PanTumor01: A global phase 2 trial of HER3-DXd in metastatic solid tumors

HERTHENA-PanTumor01:HER3 DXd在转移性实体瘤中的全球2期试验

T. Powles

T.波尔斯

690TiP

690提示

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

A phase 1, first-in-human study of DS-1471 in patients with advanced/metastatic solid tumors

第一阶段，DS-1471在晚期/转移性实体瘤患者中的首次人体研究

S. Koganemaru

S.Koganemaru

682TiP

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

Claudin-6 expression in primary and recurrent epithelial ovarian cancer: a potential therapeutic target for high-grade serous ovarian cancer

Claudin-6在原发性和复发性上皮性卵巢癌中的表达：高级别浆液性卵巢癌的潜在治疗靶点

D. Shintani

D.新谷

771P

771便士

Poster Session

海报会议

Saturday, September 14

9月14日，星期六

About the ADC Portfolio of Daiichi Sankyo

关于第一三共的ADC投资组合

The Daiichi Sankyo ADC portfolio consists of seven ADCs in clinical development crafted from two distinct ADC technology platforms discovered in-house by Daiichi Sankyo.

Daiichi Sankyo ADC组合由七个临床开发中的ADC组成，这些ADC由Daiichi Sankyo内部发现的两个不同的ADC技术平台精心打造而成。

The ADC platform furthest in clinical development is Daiichi Sankyo’s DXd ADC Technology where each ADC consists of a monoclonal antibody attached to a number of topoisomerase I inhibitor payloads (an exatecan derivative, DXd) via tetrapeptide-based cleavable linkers. The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and datopotamab deruxtecan (Dato-DXd), a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

临床开发中最深入的ADC平台是Daiichi Sankyo的DXd ADC技术，其中每个ADC由单克隆抗体组成，通过基于四肽的可切割接头连接到许多拓扑异构酶I抑制剂有效载荷（exatecan衍生物，DXd）。DXd ADC投资组合目前由ENHERTU（一种HER2导向的ADC）和datopotamab deruxtecan（Dato DXd）（一种TROP2导向的ADC）组成，它们正在与阿斯利康（AstraZeneca）联合开发并在全球商业化。

Patritumab deruxtecan (HER3-DXd), a HER3 directed ADC, ifinatamab deruxtecan (I-DXd), a B7-H3 directed ADC, and raludotatug deruxtecan (R-DXd), a CDH6 directed ADC, are being jointly developed and commercialized globally with Merck. DS-3939, a TA-MUC1 directed ADC, is being developed by Daiichi Sankyo..

Patritumab deruxtecan（HER3 DXd），一种HER3导向的ADC，ifinatamab deruxtecan（I-DXd），一种B7-H3导向的ADC，以及raludotatug deruxtecan（R-DXd），一种CDH6导向的ADC，正在与默克公司联合开发和全球商业化。DS-3939是一种TA-MUC1定向的ADC，由Daiichi Sankyo开发。。

The second Daiichi Sankyo ADC platform consists of a monoclonal antibody attached to a modified PBD payload. DS-9606, a CLDN6 directed PBD ADC, is the first of several planned ADCs in clinical development utilizing this platform.

第二个Daiichi Sankyo ADC平台由连接到修饰的PBD有效载荷的单克隆抗体组成。DS-9606是一种CLDN6定向的PBD ADC，是利用该平台进行临床开发的几个计划ADC中的第一个。

Datopotamab deruxtecan, ifinatamab deruxtecan, patritumab deruxtecan, raludotatug deruxtecan, DS-3939 and DS-9606 are investigational medicines that have not been approved for any indication in any country. Safety and efficacy have not been established.

Datopotamab deruxtecan，ifinatamab deruxtecan，patritumab deruxtecan，raludotatug deruxtecan，DS-3939和DS-9606是尚未在任何国家批准用于任何适应症的研究药物。安全性和有效性尚未确定。

About Daiichi Sankyo

关于第一三共

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular and other diseases with high unmet medical needs.

Daiichi Sankyo是一家创新的全球医疗保健公司，致力于社会的可持续发展，发现、开发和提供新的护理标准，以丰富世界各地的生活质量。凭借120多年的经验，第一三共利用其世界一流的科学技术，为癌症，心血管疾病和其他医疗需求未得到满足的疾病患者创造新的模式和创新药物。

For more information, please visit www.daiichisankyo.com..

欲了解更多信息，请访问www.daiichisankyo.com。。